GLAXO ANNOUNCES INITIATIVE FOR BETTER TB MEDICINES
LONDON, April 22 /PRNewswire/ -- Glaxo is to establish a 10 million pound, five year international research program to find better treatments for TB. Discussions with academic institutions in the UK and overseas are well advanced and will lead to a collaborative research effort later this year.
The underlying aim of this research will be to bring the power of modern molecular biology to bear on the disease.
Although the availability of anti-TB drugs and vaccines had led many to believe TB was under control, it is now considered to be a major health risk in industrialized nations as well as the third world. The Glaxo TB Initiative will comprise a highly focused industry/academia collaboration that will attempt to discover novel targets for drugs. Key areas of study will be the genetics, molecular biology and biochemistry of the enzymes involved in bacterial cell wall synthesis and, particularly the mechanism of drug resistance. The possibilities for better vaccines will also be explored. Glaxo will use information from this basic research to discover novel TB antibiotics or vaccines. Announcing the Initiative at the London School of Hygiene and Tropical Medicine's third annual public health forum ("Tuberculosis -- Back to the Future" April 18-21), Glaxo Deputy Chairman and Chief Executive Dr. Richard Sykes said: "Thoughrn biochemistry and molecular biology to point the way to new targets for drug action." Glaxo has already identified likely academic research partners and is presently discussing their TB research proposals. It is hoped the program will be finalized by this summer. In the light of the pressing public health need, the intention is to achieve a greater degree of interactive managed collaboration than is often the case in academic research. To this end, a Joint Research Body, led by Glaxo, will manage the overall program so that research is well focused, resources are used efficiently and communication of research findings between the collaborating centers is expedited. Reflecting the innovative nature of this initiative, the initial plans are for a minimum of five years, as opposed to the three years that is the norm for grants for research projects. -0- 4/22/93 /CONTACT: Nancy Pekarek of Glaxo at Research Triangle Park, 919-248-2839/ (GLX)
CO: Glaxo Holdings p.l.c. ST: IN: MTC HEA SU: PDT
CM -- CH001 -- 9250 04/22/93 09:40 EDT
|Printer friendly Cite/link Email Feedback|
|Date:||Apr 22, 1993|
|Previous Article:||GEORGIA POWER PRESIDENT TESTIFIES ON ENERGY TAX BEFORE SENATE COMMITTEE|
|Next Article:||CURRENT TECHNOLOGY FINALIZES NEGOTIATIONS|